February 14, 2020
A sample of low-income patients engaged with Omada Health’s digital diabetes prevention program (DPP), achieved weight loss but no major difference in HbA1c levels after a year of use, according to study data recently highlighted by the company.
The results — published late last year in the CDC’s Preventing Chronic Disease journal and first previewed at a 2018 public health conference — suggest...
November 14, 2018
De Novo clearance for urinary incontinence wearable. The FDA has granted De Novo clearance to Atlantic Therapeutics’ Innovo therapy device, an externally worn electrical muscle stimulator for the treatment of stress urinary incontinence. The wearable is intended for adult women as a front-line or second-line therapy, and in a multi-center randomized controlled trial recorded an 87 percent rate of...
January 28, 2018
Omada Health has made plans with the University of Nebraska Medical Center (UNMC) and Wake Forest University to conduct the largest randomized controlled study of a digital diabetes prevention tool yet, according to the digital therapeutic company.
“What’s really exciting about this clinical trial is that we also are studying how best to integrate effective, scalable preventive services,...
February 1, 2017
Chronic disease prevention and management company Solera Health has partnered with Blue Shield of California to offer Diabetes Prevention Programs (DPPs) to commercial health plan members.
Blue Shield members can access the Solera program – which offers both digital and in-person programs through a network of 1,000 CDC- recognized DPPs, – at no extra cost through Wellvolution, Blue Shield’s...